Growth Metrics

Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)

Castle Biosciences' Current Deferred Revenue history spans 2 years, with the latest figure at $3.0 million for Q3 2021.

  • On a quarterly basis, Current Deferred Revenue fell 64.08% to $3.0 million in Q3 2021 year-over-year; TTM through Sep 2021 was $3.0 million, a 64.08% decrease, with the full-year FY2020 number at $6.6 million, changed N/A from a year prior.
  • Current Deferred Revenue hit $3.0 million in Q3 2021 for Castle Biosciences, down from $6.2 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CSTL hit a ceiling of $8.4 million in Q2 2020 and a floor of $3.0 million in Q3 2021.